Resolution of Disseminated Angiosarcoma in a Kidney Transplant Recipient After Treatment With Sirolimus: A Case Report

Transplant Proc. 2022 Dec;54(10):2735-2738. doi: 10.1016/j.transproceed.2022.09.029. Epub 2022 Nov 25.

Abstract

Angiosarcoma is a rare, almost universally fatal malignant neoplasm in kidney transplant recipients. No evidence-based guidelines are available for disseminated disease. Here, we report a case of a 66-year-old woman who developed disseminated angiosarcoma 4 months after living nonrelated kidney transplant. She underwent only 2 rounds of chemotherapy because of intolerable adverse effects. Her mycophenolic acid and tacrolimus were withdrawn and sirolimus use was started. In addition to its immunosuppressant effects, sirolimus has been shown to have antineoplastic properties. Remarkably, at almost 2 years post-transplant, the patient has had complete resolution of all gross metastatic disease with only immunosuppressant medication changes. This case highlights the interesting possibility that sirolimus is an effective adjunct treatment for disseminated angiosarcoma in kidney transplant recipients.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Graft Rejection
  • Hemangiosarcoma* / drug therapy
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Kidney Transplantation* / adverse effects
  • Mycophenolic Acid / adverse effects
  • Sirolimus / adverse effects
  • Tacrolimus / adverse effects

Substances

  • Sirolimus
  • Immunosuppressive Agents
  • Tacrolimus
  • Mycophenolic Acid